Experimental cancer drug gets safety check in final patient group
NCT ID NCT05508334
Summary
This study allowed patients with advanced solid tumors who had already tried RC88 in earlier research to continue receiving the treatment while researchers monitored its safety. The main goal was to find the safest and most effective dose and see how well patients tolerated the drug. Researchers also measured whether tumors shrank and how long patients lived without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Remegen
Beijing, Beijing Municipality, China
-
Remgenen
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.